Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$8.78 USD
-0.45 (-4.88%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $8.81 +0.03 (0.34%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.78 USD
-0.45 (-4.88%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $8.81 +0.03 (0.34%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Zacks News
Top Ranked Momentum Stocks to Buy for April 4th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, April 4th:
AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval
by Zacks Equity Research
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.
New Strong Buy Stocks for March 31st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Top Ranked Momentum Stocks to Buy for March 31st
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, March 31st:
AstraZeneca's Lung Cancer Drug Tagrisso Approved in China
by Zacks Equity Research
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received approval in China.
Top Ranked Momentum Stocks to Buy for March 27th
by Zacks Equity Research
Here are four stocks with Zacks Rank #1 (Strong Buy) and strong momentum characteristics for investors to consider today, March 27th:
Can the Rally in Corvus Pharmaceuticals (CRVS) Shares Continue?
by Zacks Equity Research
Corvus Pharmaceuticals Inc (CRVS) has been on the move lately as the stock has risen by 49.5% in the past four weeks, and it is currently trading well above its 20-Day SMA